Renaissance Technologies LLC Has $1.47 Million Stock Holdings in ALX Oncology Holdings Inc. $ALXO

Renaissance Technologies LLC grew its holdings in ALX Oncology Holdings Inc. (NASDAQ:ALXO) by 73.2% during the 1st quarter, HoldingsChannel reports. The firm owned 732,599 shares of the company’s stock after purchasing an additional 309,500 shares during the quarter. Renaissance Technologies LLC’s holdings in ALX Oncology were worth $1,469,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Seven Fleet Capital Management LP bought a new stake in shares of ALX Oncology during the 4th quarter worth $133,000. Bridgeway Capital Management LLC grew its position in ALX Oncology by 111.3% in the fourth quarter. Bridgeway Capital Management LLC now owns 76,072 shares of the company’s stock valued at $86,000 after acquiring an additional 40,072 shares during the last quarter. State Street Corp grew its position in ALX Oncology by 11.0% in the fourth quarter. State Street Corp now owns 124,228 shares of the company’s stock valued at $140,000 after acquiring an additional 12,300 shares during the last quarter. Ameriprise Financial Inc. acquired a new position in ALX Oncology during the third quarter worth about $1,195,000. Finally, Two Sigma Investments LP raised its stake in ALX Oncology by 26.9% during the third quarter. Two Sigma Investments LP now owns 606,671 shares of the company’s stock worth $1,110,000 after acquiring an additional 128,737 shares in the last quarter. Institutional investors and hedge funds own 97.97% of the company’s stock.

ALX Oncology Trading Up 4.1%

Shares of ALXO stock opened at $2.01 on Thursday. ALX Oncology Holdings Inc. has a twelve month low of $0.62 and a twelve month high of $2.66. The stock’s fifty day simple moving average is $1.90 and its 200 day simple moving average is $1.95. The company has a quick ratio of 9.71, a current ratio of 9.71 and a debt-to-equity ratio of 0.07. The firm has a market capitalization of $277.94 million, a P/E ratio of -1.78 and a beta of 0.42.

ALX Oncology (NASDAQ:ALXO) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.01. As a group, sell-side analysts predict that ALX Oncology Holdings Inc. will post -0.61 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on ALXO shares. Wall Street Zen upgraded shares of ALX Oncology from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Weiss Ratings lowered shares of ALX Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, August 5th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, ALX Oncology has an average rating of “Moderate Buy” and a consensus target price of $4.60.

ALX Oncology Company Profile

ALX Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing next-generation immuno-oncology therapies. The company’s mission is to harness and amplify both innate and adaptive immune responses to improve outcomes for patients with a range of solid tumors and hematologic malignancies.

The lead candidate in ALX Oncology’s pipeline is evorpacept (ALX148), a high-affinity CD47-blocking Fc-silenced fusion protein designed to enhance macrophage-mediated phagocytosis of cancer cells when combined with standard therapeutic antibodies or immune checkpoint inhibitors.